Historical hallmarks of anticoagulation and antiplatelet agents

Current Pharmaceutical Design

Volumn 22, Issue 13, 2016, Pages 1857-1861

  Tsoucalas, Gregory ^a,e   Chevallier, Jacques ^a   Karamanou, Marianna ^b,c   Papaioannou, Theodoros ^d   Sgantzos, Markos ^e   Androutsos, George ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY OF THESSALY   (Greece)

Author keywords

Anticoagulants; Antiplatelets; History of medicine; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DICOUMAROL; HEPARIN; HIRUDIN; PENTOSAN POLYSULFATE; STREPTOKINASE; TICAGRELOR; TICLOPIDINE; UROKINASE; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; DISEASE SEVERITY; DRUG ACETYLATION; FIBRINOLYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOSIS; DRUG EFFECTS; HISTORY;

ANTICOAGULANTS; BLOOD COAGULATION; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 84964240547     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160111124615     Document Type: Article

References (58)

1. De antidotis libri ii, ed. C.G. Kühn. Claudii Galeni opera omnia, vol. 14. Galenus Med. De antidotis libri ii 14.142.14-18. Knobloch, Leipzig, 1827 (repr. Hildesheim: Olms, 1965): 1-209. (Cod: 28, 945: Med.).
2. De tumoribus praeter naturam, ed. J. Reedy. Galen. Galenus Med. De tumoribus praeter naturam 7.710.6. De tumoribus praeter naturam [Diss. University of Michigan (1968)]: 1-28. (Cod: 4, 309: Med.).
3. De renum et vesicae morbis, ed. C. Daremberg and C.É. Ruelle. Oeuvres de Rufus d’Éphèse. Rufus Med. De renum et vesicae morbis 9.1.1-9.2.5. Imprimerie Nationale, Paris, 1879 (repr. Amsterdam: Hakkert, 1963): 1-63. (Cod: 7, 110: Med.).
4. Coa praesagia, ed. É. Littré. Oeuvres complètes d’Hippocrate, vol. 5. Hippocrates Med. Et Corp. Coa praesagia 120.1-3. Baillière, Paris, 1846 (repr. Amsterdam: Hakkert, 1962): 588-732. (Cod: 13, 170: Med.).
5. Gynaeciorum libri iv, ed. J. Ilberg. Sorani Gynaeciorum libri iv, de signis fracturarum, de fasciis, vita Hippocratis secundum Soranum. (Rufus Med. De renum et vesicae morbis 9.1.1-9.2.5). [Corpus medicorum Graecorum, vol. 4. Teubner, Leipzig, 1927]: 3-152. (Cod: 42, 426: Med.).
6. De causis morborum liber, ed. C.G. Kühn. Claudii Galeni opera omnia, vol. 7. Galenus Med. De causis morborum liber 7.31.14-17. Knobloch, Leipzig, 1824 (repr. Hildesheim: Olms, 1965): 1-41. (Cod: 6, 336: Med.).
7. Iatricorum liber ix, ed. S. Zervos. Aetius Med. Iatricorum liber ix 40.86-91. “Aετίou’ Aμιδηvou λóγoς εvατoς”, Athena 23 (1911) 273-390. (Cod: 35, 935: Med.).
8. Owen CA. A history of blood coagulation. Rochester: Mayo Foundation for Medical Education and Research 2001.
9. Oeuvres complètes d'Hippocrate. Épidémies V. Littré edition, Paris, 1839-61: 217.
10. Tsoucalas G, Karamanou M, Androutsos G. Travelling through time with aspirin, a healing companion. Eur J Inflamm 2011; 9(1): 13-7.
11. Schneider O. Nicandrea, Theriaca et Alexipharmaca. Lipsia: B.G. Teubneri 1856; p. 271.
12. Pliny the Elder. Natural History. Cambridge: Harvard University Press 1989; p. 539.
13. Papavramidou N, Christopoulou-Aletra H. Medicinal use of leeches in the texts of ancient greek, roman and early byzantine writers. Intern Med J 2009; 39(9): 624-7.
14. Hunter J. The Works of John Hunter: With Notes. Volume 3. London: Longman 1835; p. 343
15. Haycraft JB, Sir Brunton TM. On the action of a secretion obtained from the medicinal leech on the coagulation of the blood. High Wycombe UK: Harrison and Sons Printers 1884; pp. 1-9.
16. Fields WS. The history of leeching and hirudin. Haemostasis 1991; 21 (Suppl 1): 3-10.
17. Richardson BW. Vacation lectures on fibrinous deposition in the heart: Its history and practical meaning. Br Med J 1860; 1(171): 259-62.
18. Ricketts BM. The Surgery of the Heart and Lungs. New York: The Grafton Press 1904.
19. Goodman J. Fibrin: Its origin and development in the animal organism, and its relation to life, health, longevity, and disease, an incontrovertible argument in favour of the hydropathic system. London: S.W. Partridge 1878: p. 101.
20. Gasperini G. Richerche morphologiche et biologiche sul genere Actinomyces. Harz. Ann Ist d'Iygiene, Universita Roma: Rome 1892; vol. 2: pp. 167-231.
21. Welsch M. Bacteriolytic Enzymes from Streptomycetes. J General Physiol 1962(45): 115-24.
22. Cooter R. Companion encyclopedia of medicine in the twentieth century. New York: Routledge 2013; p. 13.
23. Doyon M. Antithrombin. Zentralblatt für Physiologie. Leipzig: Deuticke F. 1912; vol. 25(1): p. 400.
24. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141: 757-63.
25. Jorpes JE. Heparin: A mucopolysaccharide and an active antithrombotic drug. Circulation 1959; 19: 87-91.
26. Ing ST, Rahman MA, Kjellstrand CM. Dialysis: History, Development, and Promise. Singapore: World Scientific 2012; p. 225.
27. Marcum JA. The origins of the dispute over the discovery of heparin. J History Med Allied Sci 2000; 55: 37-66.
28. Liersk R. Morphologie und Biologie der Strahlenpilze. Leipzig: Borntraeger 1921.
29. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34(3): 318-27.
30. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34(3): 318-27.
31. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: I. Isolation and characterization of fibrinolysin. J Exp Med 1934; 60: 239-54.
32. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: II. Nature of the reaction. J Exp Med 1934; 60: 255-67.
33. Tillett WS. The fibrinolytic activity of hemolytic streptococci. Bacteriol Rev 1938; 2: 161-216.
34. Degryse B. The urokinase receptor system as strategic therapeutic target: challenges for the 21st century. Curr Pharm Des 2011; 17(19): 1872-3.
35. Biggs R. MacFarlane RG. Human blood coagulation and its disorders. Second ed. New York: Oxford 1957.
36. Weimar W, Stibbe J, van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2(8254): 1018-20.
37. Roderick LM. A problem in the coagulation of the blood. Sweet clover disease of cattle. Am J Physiol 1929; 96: 413-25.
38. Matis P, Matis U, Köstlin RG. The importance of veterinary medical research for human medicine. History of coagulation inhibition by dicumarol (analogs). Tierarztl Prax Suppl 1985; 1: 195-202.
39. Norn S, Permin H, Kruse E, Kruse PR. On the history of vitamin K, dicoumarol and warfarin. Dan Medicinhist Arbog 2014; 42: 99-119.
40. Link KP. The anticoagulant dicumarol. Bull Chic Med Soc 1948; 51(4): 57-62.
41. Campbell HA, Smith WK, Roberts WL, Link KP. Studies on the hemorrhagic sweet clover disease. II. The bioassay of hemorrhagic concentrates by following the prothrombin level in the plasma of rabbit blood. J Biol Chem 1941; 138: 1-20.
42. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem 1941; 138(2): 513-27.
43. Link KP. Can we look forward to better anticoagulants than heparin and dicumarol? Bull Chic Med Soc 1949; 51(39): 748.
44. Mann CC, Pulmmer ML. The Aspirin Wars. New York: Knopf 1991; pp. 23-6.
45. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23(4): 349-56.
46. Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967; 2(7514): 495-7.
47. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47(9): 2169-80.
48. Landau R., Achilladelis B., Scriabine A. Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press 1999; p. 408
49. Maffrand JP, Eloy F. New anti-inflammatory drugs related to Tinoridine. Eur J Med Chem 1974(9): 483.
50. Maffrand JP. The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today? C. R. Chimie 2012; 15: 737-43.
51. Moliterno DJ, Kristensen SD, Caterina R.Therapeutic Advances in Thrombosis. Oxford UK: John Wiley & Sons 2012.
52. Johnson EA, Kirkwood TB, Stirling Y, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35(3): 586-91.
53. Annotation. Heparin, Low molecular weight heparin and heparin analogues. Br J Haernatol 1984; 58: 385-90.
54. Wolff HP, Fleckensteinv A, Philipp EO. Drug Research and Drug Development in the 21st Century: Science and Ethics. Berlin: Springer Science & Business Media 2012; p. 1.
55. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents -the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20(1): 37-52.
56. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014; 349: g4670.
57. Fassiadis N. Rivaroxaban, the first oral, direct factor Xa inhibitor. Expert Opin Pharmacother 2009; 10(18): 2945-6.
58. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012; 125(23): 2914-21.